Supernus
SUPN | NASDAQ
$28.83
-$0.89 (-2.99%)
At close: Nov 16, 2026, 4:00 PM ET
$28.83
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Supernus Company Profile
Company profile explainedCompany Profile
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
Key Executives
| Name | Position |
|---|---|
| Jack A. Khattar | President, CEO & Director |
| Joseph J. Ciaffoni | Chief Executive Officer & Director |
| Jeffrey W. Burris | Chief Legal Officer |
| Ryan Preblick | Chief Financial Officer |
| Alice G. Givens | Company Secretary |
| Angela Colon-Mahoney | Chief Human Resources Officer |
| Ann Wheeler | Chief Medical Officer |
| Christian Heidbreder | Chief Scientific Officer |
| Jason Thompson | Vice President of Investor Relations |
| Ken Morici | Senior Vice President of Manufacturing & Supply |
| Kevin L. Espinoza | Chief Integrity & Compliance Officer |
| Patrick A. Barry | Chief Commercial Officer |
| Timothy C. Dec | Senior VP & CFO |
| Vanessa Procter | Executive Vice President of Corporate Affairs |
Supernus
| Country | United States |
| IPO Date | Apr 30, 2012 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 827 |
| CEO | Jack A. Khattar |
Contact Details
9715 Key West Avenue Rockville,
Maryland 20850 United States
Stock Details
| Ticker Symbol | SUPN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625297 |
| CUSIP Number | 45579U109 |
| ISIN Number | US45579U1097 |
| SIC Code | 2834 |
Recent News
- 6 days ago / globenewswire.comSupernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
- 8 days ago / benzinga.comThis Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- 13 days ago / 247wallst.comBuy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
- 14 days ago / fool.comWhy Indivior Pharmaceuticals Stock Topped the Market Today
- 18 days ago / seekingalpha.comSupernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
- 18 days ago / zacks.comSupernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
- 18 days ago / marketbeat.comSupernus Pharmaceuticals Q3 Earnings Call Highlights
- 18 days ago / benzinga.comSupernus Pharmaceuticals Q3 2026 Earnings Call Transcript
- 18 days ago / globenewswire.comSupernus Announces Third Quarter 2026 Financial Results
- 19 days ago / prnewswire.comUpdated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
Add to Watchlist
Select watchlists to add or remove SUPN